Our Blog
See below for an opinion on current matters around the world.
The Good, the Bad, and the Ugly: Australia’s HTA Review Final Report
Déjà vu all over again?: Australia’s industrial policy debate
Pharmaceuticals Take Centre Stage in Australian Election Campaign
Will she be right?: the ‘non-issues’ of the 2022 Australian federal election
Australians now understand there is a 'queue' for new health technologies
Medicines Australia Strategic Agreement is 'the end of the beginning'
NICE methods review, UK Life Sciences Strategy and the life sciences industry: lessons for Australia
Fair dinkum or collywobbles? Life sciences and the Australia – UK free trade agreement
Opportunities for the Life Science Industry in Australia post-COVID
More risk for government this time around in agreement negotiation
The next 20-year PBS agenda: government commitments to new medicines spending
PBS New Medicines Funding Guarantee: echoes of elections past ...
This could get messy: Trump’s New ‘Most Favoured Nation’ Executive Order on Medicine Pricing
When profit isn’t everything: 46,000 years of cultural history vs the iron ore spot price
What trade war?: Western and Chinese life science companies just get on with it
Australia's National Medicines Policy is outdated and in need of review
A minor issue?: minor parties and independents in the 2019 Australian election
UK-Australia trade deal an opportunity for life sciences in both countries
Brexit and life sciences: a British conundrum, an Australian perspective